88 related articles for article (PubMed ID: 2480393)
1. [Field trial of the early detection in patients with ovarian cancer].
Kobayashi H; Sumimoto K; Terao T; Kawashima Y; Kouda M
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1743-9. PubMed ID: 2480393
[TBL] [Abstract][Full Text] [Related]
2. [Serodiagnostic tests by factor analysis and stepwise discriminating analysis with tumor markers for the detection of ovarian cancer].
Kobayashi H; Sumimoto K; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1903-10. PubMed ID: 2480396
[TBL] [Abstract][Full Text] [Related]
3. [Field trial for the early detection of patients with ovarian cancer--discrimination of ovarian cancer patients by the statistical analysis using Mahalanobis' generalized distance].
Kobayashi H; Sumimoto K; Terao T; Kawashima Y; Okada K
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Feb; 44(2):174-80. PubMed ID: 1372032
[TBL] [Abstract][Full Text] [Related]
4. [Field trial for the early detection of patients with ovarian cancer].
Kobayashi H; Terao T
Rinsho Byori; 1992 Feb; 40(2):139-45. PubMed ID: 1374818
[TBL] [Abstract][Full Text] [Related]
5. [Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms].
Yabushita H; Masuda T; Hattori A; Noguchi M; Ito Y; Nakanishi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Sep; 37(9):1883-92. PubMed ID: 2997349
[TBL] [Abstract][Full Text] [Related]
6. Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin.
Yabushita H; Sawaguchi K; Hieda S; Ogawa A; Tomatsu A; Noguchi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Feb; 41(2):217-24. PubMed ID: 2566639
[TBL] [Abstract][Full Text] [Related]
7. [A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers].
Kataoka A; Yakushiji M
Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):47-54. PubMed ID: 2157782
[TBL] [Abstract][Full Text] [Related]
8. [New prospects in the combined use of tumor markers in epithelial neoplasms of the ovary].
Indraccolo SR; Cecchi A; Thodos A; Brandi S; Carta G
Ann Ostet Ginecol Med Perinat; 1991; 112(1):36-40. PubMed ID: 1929097
[TBL] [Abstract][Full Text] [Related]
9. [Significance of tumor markers in the treatment of patients with ovarian malignancies].
Tomoda Y; Kano T; Furuhashi Y; Mizuno K; Kamiya N; Mizuno K; Sakakibara K; Ohta M
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3027-33. PubMed ID: 2445293
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis of skeletal metastases by serum tumor markers].
Shinozaki T; Chigira M
Nihon Seikeigeka Gakkai Zasshi; 1991 Aug; 65(8):441-6. PubMed ID: 1720162
[TBL] [Abstract][Full Text] [Related]
11. [Clinical evaluation of a combination assay of CEA, CA-19-9 and TPA in patients with colorectal cancer].
Nishida O; Shiroto H; Satoh N; Nakajima Y; Manabe K; Kondoh Y; Sano F; Uchino J
Gan No Rinsho; 1988 Aug; 34(9):1096-100. PubMed ID: 3172515
[TBL] [Abstract][Full Text] [Related]
12. [Comparative evaluation of diagnostic significance of carbohydrate antigen CA125 and cancer-embryonal antigen in ovarian cancer].
Lapchenkov VI; Dudarev AL; Vinokurov VL; Iurkova LE; Barbanel EIu
Vestn Rentgenol Radiol; 1993; (5):30-1. PubMed ID: 7801580
[TBL] [Abstract][Full Text] [Related]
13. [Tumor marker--screening for gynecological cancer; personal experience. Utility of tumor markers in screening of ovarian cancer].
Kimura E; Kobayashi S; Terashima Y
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2443-50. PubMed ID: 2260879
[TBL] [Abstract][Full Text] [Related]
14. [Tumor markers in ovarian cancer].
Lahousen M
Jugosl Ginekol Perinatol; 1987; 27(3-4):73-5. PubMed ID: 3481005
[No Abstract] [Full Text] [Related]
15. [Analysis of serum CA125, CEA, AFP, LDH levels and LDH isoenzymes in patients with ovarian tumors--correlation between tumor markers and histological types of ovarian tumors].
Konishi I; Fujii S; Okamura H; Sakahara H; Endo K; Torizuka K; Suzuki A; Mori T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):827-36. PubMed ID: 2426374
[TBL] [Abstract][Full Text] [Related]
16. [Clinical evaluation of four tumor markers (CEA, TPA, CA50 and CA72-4) in colorectal cancer].
Koizumi F; Odagiri H; Fujimoto H; Kawamura T; Ishimori A
Rinsho Byori; 1992 May; 40(5):523-8. PubMed ID: 1507478
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
[TBL] [Abstract][Full Text] [Related]
18. Prediction of clinical course and recurrence of human ovarian cancer by several serum tumor markers.
Kikuchi Y; Kita T; Iwano I; Kuki E; Oomori K; Kizawa I
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan; 41(1):69-76. PubMed ID: 2926196
[TBL] [Abstract][Full Text] [Related]
19. [Clinical evaluation of tumor markers in patients with colorectal cancer].
Naritaka Y; Ogawa K; Matsumoto N; Hosokawa T; Kikuchi T; Koyama N; Haga S; Kajiwara T; Sakakibara N
Gan No Rinsho; 1987 Aug; 33(10):1274-80. PubMed ID: 2444727
[TBL] [Abstract][Full Text] [Related]
20. [Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer].
Schröck R; Hafter R; Schmid L; Babic R; Ulm K; Gössner W; Graeff H
Geburtshilfe Frauenheilkd; 1986 Jan; 46(1):1-10. PubMed ID: 2420679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
